2984963-50-8
Chemical Structure
Sovesudil hydrochloride
Synonym(s): PHP-201 hydrochloride; AMA0076 hydrochloride
- CAS No.: 2984963-50-8
- Formula:C23H23ClFN3O3
- Molecular Weight:443.90
IUPAC Name: propyl 2'-(aminomethyl)-5'-((3-fluoropyridin-4-yl)carbamoyl)-[1,1'-biphenyl]-3-carboxylate hydrochloride
InChIKey: XHOTYNSTYWPINR-UHFFFAOYSA-N
SMILES: O=C(C1=CC(C2=CC(C(NC3=C(F)C=NC=C3)=O)=CC=C2CN)=CC=C1)OCCC.[H]Cl
Biological Activity: Sovesudil (PHP-201) hydrochloride is a potent, ATP-competitive, locally acting Rho kinase (ROCK) inhibitor with IC50s of 3.7 and 2.3 nM for ROCK-I and ROCK-II, respectively. Sovesudil hydrochloride lowers intraocular pressure (IOP) without inducing hyperemia[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Sovesudil hydrochloride | 99.45% | Sovesudil (PHP-201) hydrochloride is a potent, ATP-competitive, locally acting Rho kinase (ROCK) inhibitor with IC50s of 3.7 and 2.3 nM for ROCK-I and ROCK-II, respectively. Sovesudil hydrochloride lowers intraocular pressure (IOP) without inducing hyperemia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Sovesudil hydrochloride (Standard) | ≥98% | Sovesudil hydrochloride (Standard) is the analytical standard of Sovesudil (hydrochloride) (HY-109191A). This product is intended for research and analytical applications. Sovesudil (PHP-201) hydrochloride is a potent, ATP-competitive, locally acting Rho Kinase (ROCK) inhibitor with IC50s of 3.7 and 2.3 nM for ROCK-I and ROCK-II, respectively. Sovesudil hydrochloride lowers intraocular pressure (IOP) without inducing hyperemia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Van de Velde S, et al. AMA0076, a novel, locally acting Rho kinase inhibitor, potently lowers intraocular pressure in New Zealand white rabbits with minimal hyperemia. Invest Ophthalmol Vis Sci. 2014;55(2):1006-1016. Published 2014 Feb 18. [Content Brief]
- [2]. Ha A, et al. Sovesudil (locally acting rho kinase inhibitor) for the treatment of normal-tension glaucoma: the randomized phase II study [published online ahead of print, 2021 Jul 28]. Acta Ophthalmol. 2021;10.1111/aos.14949. [Content Brief]
